Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Blinatumomab
Treatment for Acute lymphoid leukemia
Typical Dosage: 9 mcg/day for week 1, then 28 mcg/day continuous IV infusion
Effectiveness
85%
Safety Score
40%
Clinical Trials
127
Participants
7K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
9 mcg/day for week 1, then 28 mcg/day continuous IV infusion
Time to Effect
2-4 weeks
Treatment Duration
Continuous IV infusion for 28-day cycles (2-4 cycles)
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$30,000
Side Effect Mgmt:$40,000
Total Annual:$270,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$450,000
Cost per Remission
$600,000
Comparison vs Standard Chemotherapy
Cost Difference
+$150,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Blinatumomab Outcomes
for Acute lymphoid leukemia
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+60%
Remission Rate
+45%
Common Side Effects
Cytokine Release Syndrome (CRS)
+10%
Neurologic toxicities
+15%
Fever
+40%
Headache
+25%
Neutropenia
+20%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Blinatumomab in Acute lymphoid leukemia
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
NCT06111625RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Chengdu, China
Started: Sep 10, 2023
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT
NCT06075238NOT YET RECRUITINGPHASE2
68 participants
INTERVENTIONAL
Chengdu, China
Started: Oct 1, 2023
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113ACTIVE NOT RECRUITINGPHASE2
18 participants
INTERVENTIONAL
Hefei, China +6 more
Started: Jul 23, 2024
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894RECRUITINGPHASE3
160 participants
INTERVENTIONAL
Buenos Aires, Argentina +114 more
Started: Dec 15, 2022
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
NCT05519579RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Atlanta, United States
Started: Jun 30, 2023
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576RECRUITINGPHASE3
6.43K participants
INTERVENTIONAL
Brussels, Belgium +137 more
Started: Jul 13, 2020
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
NCT06930105NOT YET RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Started: Sep 1, 2025
Completed Clinical Trials
8 completed trials for Blinatumomab in Acute lymphoid leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT00560794COMPLETEDPHASE2
21 participants
INTERVENTIONAL
Ulm, Germany +5 more
Started: Jan 1, 2008
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT01471782COMPLETEDPHASE1, PHASE2
93 participants
INTERVENTIONAL
Aurora, United States +29 more
Started: Jan 1, 2012
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179COMPLETEDPHASE2
225 participants
INTERVENTIONAL
Duarte, United States +38 more
Started: Dec 1, 2011
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
NCT06649006COMPLETEDPHASE1
6 participants
INTERVENTIONAL
Akita, Japan +5 more
Started: Jan 8, 2025
Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT03476239COMPLETEDPHASE3
121 participants
INTERVENTIONAL
Beijing, China +22 more
Started: Oct 18, 2017
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT02393859COMPLETEDPHASE3
111 participants
INTERVENTIONAL
Ciudad Autonoma de Buenos Aires, Argentina +102 more
Started: Nov 10, 2015
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
NCT05557110COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Suzhou, China
Started: Sep 8, 2022
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01207388COMPLETEDPHASE2
116 participants
INTERVENTIONAL
Graz, Austria +74 more
Started: Nov 1, 2010
Showing 20 of 141 total trials